Table 1.
Patient demographics and baseline disease characteristics
| Feladilimab mg/tremelimumab mg | ||||||
|---|---|---|---|---|---|---|
| Population | 8/75 (N = 1) | 24/75 (N = 1) | 8/225 (N = 5) | 80/75 (N = 3) | 24/225 (N = 16) | Total (N = 26) |
| Sex, n (%) | ||||||
| Female | 1 (100) | 1 (100) | 3 (60) | 0 | 4 (25) | 9 (35) |
| Male | 0 | 0 | 2 (40) | 3 (100) | 12 (75) | 17 (65) |
| Age (years), median (range)a |
51 (51–51) |
51 (51–51) |
62 (45–72) |
66 (58–83) |
71 (36–83) |
65 (36–83) |
| Race, n (%)b | ||||||
| White/Caucasian | 1 (100) | 1 (100) | 5 (100) | 3 (100) | 14 (88) | 24 (92) |
| Black/African American | 0 | 0 | 0 | 0 | 1 (6) | 1 (4) |
| Primary tumor type, n (%)c | ||||||
| Bladder | 0 | 0 | 0 | 1 (33) | 3 (19) | 4 (15) |
| HNSCC | 0 | 0 | 1 (20) | 0 | 7 (44) | 8 (31) |
| Melanoma | 1 (100) | 1 (100) | 2 (40) | 0 | 1 (6) | 5 (19) |
| NSCLC | 0 | 0 | 2 (40) | 2 (67) | 5 (31) | 9 (35) |
| Time since initial diagnosis (days), median (range)d |
676 (676–676) |
512 (512–512) |
640 (175–2019) |
251 (92–470) |
372 (27–1545) |
411 (27–2019) |
| Prior therapies, n (%) | ||||||
| Immunotherapy | 1 (100) | 1 (100) | 5 (100) | 3 (100) | 13 (81) | 23 (88) |
| Chemotherapy | 0 | 0 | 4 (80) | 3 (100) | 13 (81) | 20 (77) |
| Radiotherapy | 1 (100) | 1 (100) | 5 (100) | 1 (33) | 9 (56) | 17 (65) |
| Surgery | 1 (100) | 1 (100) | 4 (80) | 2 (67) | 14 (88) | 22 (85) |
aAge is imputed when full date of birth is not provided; bone patient in the 24/225 mg dose group reported race as Multiple; chistology at initial diagnosis reported as adenocarcinoma in 10 patients, squamous cell carcinoma in 9 patients, and other in 7 patients; dtime since diagnosis is defined as earliest treatment start date minus the initial diagnosis date plus 1 day
HNSCC head and neck squamous cell carcinoma, NSCLC non-small cell lung cancer